Entyvio (vedolizumab) is used to treat ulcerative colitis (UC) and Crohn’s disease. In these conditions, the body’s immune system attacks healthy tissues in the gut, causing abdominal pain, blood in the stool, and diarrhea. 

People with Crohn’s and ulcerative colitis (UC) have chronic inflammation of the gut with an excess of white blood cells that target the gastrointestinal (GI) tract. The alpha-4-beta-7 T-cell attaches to the MAdCAM-1 receptor in the gut, causing increased inflammation.  

Entyvio belongs to a class of drugs known as monoclonal antibodies and works by blocking this connection so that excess white blood cells can’t enter the gut tissue. Entyvio is very specialized to specifically target GI proteins only. When T-cells can’t enter the gut, inflammation is reduced as well as the symptoms of Crohn’s and UC.